So Morgan Stanley’s chief equity strategist Michael Wilson just did something that’ll make your portfolio smile: he bumped up his S&P 500 target from 7,200 to 7,800 for the end of 2026. That’s an 18% jump from where we’re sitting now at around 6,600. Not too shabby for a year’s work, right?
Here’s the thing that’s got Wilson all fired up – he thinks we’re not just riding the same old bull market wave. Nope, he’s calling this a brand new bull market that kicked off in late April after that gnarly crash earlier in the year. “We’re in the midst of a new bull market and earnings cycle,” Wilson says, and honestly, when someone at Morgan Stanley gets this excited about earnings, you should probably pay attention.
The Earnings Story That Actually Makes Sense
Wilson’s not just throwing darts at a board here. His team is betting on some serious earnings growth – they’re expecting S&P 500 earnings to hit $317 per share in 2026 (that’s a 17% bump) and then cruise to $356 in 2027. The secret sauce? A cocktail of AI efficiency gains, friendly tax policies, and companies finally getting some pricing power back.
And before you start hyperventilating about valuations, Wilson’s got you covered. Yeah, stocks aren’t exactly cheap with a P/E ratio around 22, but he argues many companies aren’t as expensive as they look once you factor in that earnings growth. “Some areas may appear somewhat frothy,” he admits (looking at you, speculative growth stocks), but the fundamentals are solid.
Small Caps: The Comeback Kid
Here’s where it gets interesting – Wilson thinks small caps are about to have their revenge tour. The Russell 2000 has been the market’s sad puppy this year, up only 5.8% while the S&P 500 strutted around with its 13% gains. But Wilson’s team sees small caps finally outperforming their big brothers in 2026.
Why? Think about it – small companies tend to be more nimble when the economic winds shift, and with interest rates potentially coming down, these smaller players won’t be drowning in debt costs anymore.
The Sectors Getting Love
Wilson’s crystal ball is particularly bullish on financials, industrials, and healthcare. Banks love lower rates (more lending, less stress), while healthcare is getting a double shot of good news from rate cuts and a potential M&A bonanza. Biotech, in particular, tends to go on a tear 6-12 months after the Fed starts cutting rates.
Consumer cyclicals should also outshine the boring staples – because when people feel good about the economy, they buy more stuff they don’t absolutely need.
The Bottom Line
Look, nobody has a crystal ball (not even Morgan Stanley), but Wilson’s call isn’t based on wishful thinking. It’s grounded in corporate earnings momentum, AI-driven efficiency gains, and a shift toward sectors that have been sitting on the bench. Whether we hit that 7,800 target or not, the underlying trends he’s highlighting – small cap resurgence, sector rotation, and earnings growth – are worth watching.
Just remember: past performance doesn’t guarantee future results, but sometimes the smart money knows something the rest of us are still figuring out.